Search for "acetal formation" in Full Text gives 15 result(s) in Beilstein Journal of Organic Chemistry.
Beilstein J. Org. Chem. 2026, 22, 289–343, doi:10.3762/bjoc.22.21
Graphical Abstract
Scheme 1: Mechanistic overview of enzymes involved in ring-size-altering reactions: A: Difference in ionisati...
Scheme 2: A: Ring contraction through involvement of carbocationic intermediates in thujane monoterpene biosy...
Scheme 3: Examples of concerted ring expansions of carbocation intermediates in PxaTPS8-catalysed cyclisation...
Scheme 4: Sequential ring expansions during astellifadiene (17) synthesis reported by Abe and co-workers.
Scheme 5: Cyclobutane ring expansion and sequential ring contractions catalysed by the synthase AITS in the b...
Scheme 6: Ring expansion and transannular ring contraction of a cyclopentane to cyclobutane in the biosynthes...
Scheme 7: Computationally elucidated concerted cyclisations/alkyl/hydride shifts during the biosynthesis of t...
Scheme 8: Cyclisation events and 6→5-ring contraction during the construction of epi-isozizaene (26) catalyse...
Scheme 9: Transannular cyclisations and 4→5-membered ring expansion through dyotropic 1,2-rearrangement of al...
Scheme 10: Ring expansion in presilphiperfolan-8b-ol (31) biosynthesis and ring contraction of the presilphipe...
Scheme 11: Ring contraction via transannular cyclopropanation and opening of cyclopropane in the biosynthesis ...
Scheme 12: The crucial CYP450-catalysed oxidative rearrangement defining the skeleton in gibberellin biosynthe...
Scheme 13: CYP450-mediated oxidation of cyclopentane methylene expanding the 8-membered ring in the biosynthes...
Scheme 14: CYP450-mediated oxidation of an exocyclic methyl group to effect transannular cyclisation across th...
Scheme 15: Non-enzymatic transannular aldol reaction enables the formation of the 5/13/3-tricyclic ring system...
Scheme 16: A: Oxidative ring expansion of a cyclopentane by incorporation of a methyl group in the biosynthesi...
Scheme 17: Rearrangement and ring expansion in the construction of the complex bridged carbon framework of and...
Scheme 18: Ketoglutarate-mediated oxidations of preaustinoid A1 (53) en route to complex meroterpenoids, B-rin...
Scheme 19: Proposed putative biosynthetic formation of the tigliane skeleton from an E,E,Z-triene.
Scheme 20: Photocatalytic tandem ring expansion/contraction of santonin to give photosantonin products and gua...
Scheme 21: A: Proposed biosynthesis of stelleroid B (66) from stelleranoid I (65) by ketol rearrangement; B: o...
Scheme 22: Singular examples of A,B-ring contractions and expansions in the biosynthesis of sesquiterpenoids e...
Scheme 23: A: plausible proposed biosynthetic pathway for the tigliane/ingenane skeletal rearrangement and 1,2...
Scheme 24: A: Multiple ring-size alterations during xenovulene A (90) biosynthesis; B: Ring contraction and re...
Scheme 25: Proposed biosyntheses of the complex, polycyclic terpenoid illisimonin A (97) and the bridged antro...
Scheme 26: Proposed biogenetic origin for the meroterpenoid liphagal (104) via epoxide-mediated ring expansion....
Scheme 27: Proposed biogenetic origin for the ring-contracted members of the taiwaniaquinol family.
Scheme 28: A: Schenck ene/Hock/Aldol cascade effecting B-ring contraction in atheronal B (113); B: Selective C...
Scheme 29: A: D-ring expansion of buxenone (118) via cyclopropanation towards buxaustroine A (119); B: Propose...
Scheme 30: Biosynthetic origin of alstoscholarinoids A (124) and B (125) via cascade oxidative rearrangement c...
Scheme 31: Biogenetic origin of the hedgehog signalling inhibitor cyclopamine (129) by tandem ring contraction...
Scheme 32: Proposed biogenetic origin of the B-ring contracted spirocyclic triterpenoid spirochensilide A (131...
Scheme 33: A: Proposed B-ring contraction during the biosynthesis of holophyllane A (133); B: B-ring contracti...
Scheme 34: Radical and ionic/polar mechanisms for the C-ring-contracted triterpenoids phomopsterone B (139) an...
Scheme 35: A: Plausible mechanism for the formation of schiglautone A (144) from anwuweizic acid (145); B: Pro...
Scheme 36: Reported biosynthetic proposal for the formation of B-ring expanded triterpenoids rhodoterpenoids A...
Scheme 37: A: Final reaction step in the synthesis of euphorikanin A (154), benzilic acid-type ring contractio...
Scheme 38: Tricyclic ring expansion in the Gui synthesis of gibbosterol A (158) and sarocladione (160) via Ru-...
Scheme 39: A: A-ring expansion during the Gui synthesis of rubriflordilactone B (161); B: Mechanism for the bi...
Scheme 40: Photosantonin rearrangement effects A/B ring contraction/expansion in Li’s synthesis of the complex...
Scheme 41: Tandem A/B ring expansion/contraction of an ergosterol derivative via pinacol rearrangement in the ...
Scheme 42: Synthetic studies towards cyclocitrinol (179) by A) the semisynthetic approach by Gui et al. using ...
Scheme 43: A: Bioinspired synthesis of spirochensilide A (131) by the Heretsch group via selective 8,9-epoxida...
Scheme 44: Baran’s synthesis of cortistatin A (191), expanding the B-ring through a cyclopropane fragmentation....
Scheme 45: Ding’s total synthesis of retigeranic acid (198) showcasing sequential 6→5 ring contractions.
Scheme 46: A: Oxa-di-π-methane (ODPM) rearrangement of a bicyclic ketone en route to silphiperfolenone (203); ...
Scheme 47: Biomimetic synthesis of liphagal (104) from sclareolide (221) by George and co-workers.
Scheme 48: Wu’s bioinspired synthesis of cucurbalsaminones B (224) and C (225) by photocatalytic oxa-di-π-meth...
Scheme 49: Baran’s total synthesis of maoecrystal V (230) featuring a pinacol rearrangement for ring expansion...
Scheme 50: A: Ketol rearrangement leading to ring contraction in the total synthesis of preaustinoid B; B: Ben...
Scheme 51: A: Scheidt’s synthesis of isovelleral (251) by pinacol rearrangement triggered by Mitsunobu conditi...
Scheme 52: Biomimetic transformations of simplified test substrates related to Euphorbia diterpenoids.
Scheme 53: A: First generation synthesis of taiwaniaquinones by benzilic acid-type rearrangement of the B-ring...
Scheme 54: A: Norrish type 1 radical recombination leading to ring contraction en route to cuparenone (272): 1...
Scheme 55: Ring contraction of a bridged D-ring system in the total synthesis of andrastatin D (280), terrenoi...
Scheme 56: Biomimetic synthesis of hyperjapone A (284) and hyperjaponol C (285) by George et al.
Scheme 57: Heretsch’ synthesis of dankastarones A (288) and B (289), swinhoeisterol A (290), and periconiaston...
Scheme 58: A: Zhang’s ring contraction during the synthesis of stemar-13-ene (295) by pinacol rearrangement; B...
Scheme 59: Trauner’s biomimetic synthesis of preuisolactone A (307) featuring a ring contraction via benzilic ...
Scheme 60: Bioinspired approaches for ring contraction/expansion reactions in the synthesis of alstoscholarino...
Scheme 61: A: Sarpong and Li, Wang and co-workers’ ring expansion of cephanolide A (313) to reach harringtonol...
Beilstein J. Org. Chem. 2025, 21, 2657–2693, doi:10.3762/bjoc.21.206
Graphical Abstract
Scheme 1: Representatives of steroid alkaloid classes. Marked in blue is the steroidal cholestane framework, ...
Scheme 2: Subclasses of Veratrum alkaloids: jervanine, veratramine and cevanine-type [8].
Scheme 3: Flow chart presentation of the synthesis of (−)-englerin A developed by the Christmann group [10].
Scheme 4: Structures and year of synthesis of the three types of Veratrum alkaloids reported in the literatur...
Scheme 5: Key step in the synthesis of cyclopamine (6) by the Giannis group [21].
Scheme 6: Overview of the semisynthesis of cyclopamine (6) reported by the Giannis group in 2009 [21].
Scheme 7: Key steps in the synthesis of cyclopamine (6) by the Baran group [23].
Scheme 8: Overview of the total synthesis of cyclopamine (6) by the Baran group in 2023 [23].
Scheme 9: Key steps in the synthesis of cyclopamine (6) by the Zhu/Gao group [25].
Scheme 10: Overview of the total synthesis of cyclopamine (6) by the group of Zhao/Gao in 2023 [25].
Scheme 11: Key steps in the synthesis of cyclopamine (6) by the Liu/Qin group [26].
Scheme 12: Overview of the semisynthesis of cyclopamine (6) by the Liu/Qin group in 2024 [26].
Scheme 13: Key steps in the synthesis of jervine (12) by the Masamune group [14].
Scheme 14: Overview of the total synthesis of jervine (12) by the Masamune group in 1968 [14].
Scheme 15: Color-coded schemes of the presented cyclopamine (6) syntheses by Giannis, Baran, Zhu/Gao, and Liu/...
Scheme 16: Key steps in the total synthesis of veratramine (13) by the Johnson group [15].
Scheme 17: Overview of the total synthesis of veratramine (13) by the Johnson group in 1967 [15].
Scheme 18: Key steps in the synthesis of veratramine (13) by the Zhu/Gao group [25].
Scheme 19: Shortened overview of the total synthesis of veratramine (13) by the Zhu/Gao group in 2023 [25].
Scheme 20: Key steps in the synthesis of veratramine by the Liu/Qin group [26].
Scheme 21: Overview of the semisynthesis of veratramine (13) by the Liu/Qin group in 2024 [26].
Scheme 22: Key steps in the synthesis of veratramine (13) by the Trauner group [27].
Scheme 23: Overview of the total synthesis of veratramine (13) by the Trauner group in 2025 [27].
Scheme 24: Key steps in the synthesis of verarine (14) by the Kutney group [16-19].
Scheme 25: Overview of the total synthesis of verarine (14) by the Kutney group reported 1962–1968 [16-19].
Scheme 26: Color-coded schemes of the presented veratramine-type alkaloid synthesis of Zhu/Gao, Liu/Qin and Tr...
Scheme 27: Structures of veracevine (86), veratridine (87), and cevadine (88).
Scheme 28: Key step in the semisynthesis of verticine (15) by the Kutney group (1977) [20,46].
Scheme 29: Overview of the semisynthesis of verticine (15) by the Kutney group (1977) [20,46].
Scheme 30: Key step of the total synthesis of (±)-4-methylenegermine (17) by the Stork group (2017) [22].
Scheme 31: Overview of the total synthesis of (±)-4-methylenegermine (17) by the Stork group (2017) [22].
Scheme 32: Key step of the total synthesis of heilonine (16) by Cassaidy and Rawal (2021) [24].
Scheme 33: Overview of the total synthesis of heilonine (16) by Cassaidy and Rawal (2021) [24]. FGI: functional gr...
Scheme 34: Key steps of the synthesis of heilonine (16) by Dai and co-workers (2024) [28].
Scheme 35: Overview of the total synthesis of heilonine (16) by Dai and co-workers (2024) [28].
Scheme 36: Key steps of the total synthesis of zygadenine (18) reported by Luo and co-workers [29].
Scheme 37: Overview of the total synthesis of zygadenine (18) by Luo and co-workers (2023) [29].
Scheme 38: Key step of the divergent total syntheses of highly oxidized cevanine-type alkaloids by Luo and co-...
Scheme 39: Divergent syntheses of highly oxidized cevanine-type alkaloids by Luo and co-workers (2024) [30].
Scheme 40: Color-coded overview of the presented cevanine-type alkaloid syntheses [10,20,22,24,28-30,46]. LLS: longest linear sequen...
Beilstein J. Org. Chem. 2024, 20, 2171–2207, doi:10.3762/bjoc.20.187
Graphical Abstract
Figure 1: Examples of compounds covered in this review categorized in six sub-classes (see text).
Figure 2: Examples of compounds not covered in this review.
Figure 3: Wrongly assigned and thus obsolete structures (details will be discussed in the respective chapters...
Figure 4: Alternariol with the correct IUPAC numbering and an occasionally used numbering based on the biphen...
Figure 5: Alternariol O-methyl ethers.
Figure 6: Alternariol O-glycosides.
Figure 7: Alternariol O-acetates and O-sulfates.
Figure 8: 2-Hydroxy- and 4-hydroxy-substituted alternariol and its O-methyl ethers.
Figure 9: Chloro- and amino-substituted alternariol and its O-methyl ethers.
Figure 10: Presumed alternariol derivatives with non-canonical substitution pattern.
Figure 11: Alternariol derivatives with the 1-methyl group hydroxylated.
Figure 12: Verrulactones: pseudo-dimeric derivatives of altertenuol and related compounds.
Figure 13: Biaryls formed by reductive lactone opening and/or by decarboxylation.
Figure 14: Altenuene and its diastereomers.
Figure 15: 9-O-Demethylated altenuene diastereomers.
Figure 16: Acetylated and methylated altenuene diastereomers.
Figure 17: Altenuene diastereomers modified with lactic acid, pyruvic acid, or acetone.
Figure 18: Neoaltenuene and related compounds.
Figure 19: Dehydroaltenusin and its derivatives.
Scheme 1: Equilibrium of dehydroaltenusin in polar solvents [278].
Figure 20: Further quinoid derivatives.
Figure 21: Dehydroaltenuenes.
Figure 22: Complex aggregates containing dehydroaltenuene substructures and related compounds.
Figure 23: Dihydroaltenuenes.
Figure 24: Altenuic acids and related compounds.
Figure 25: Cyclopentane- and cyclopentene-fused derivatives.
Figure 26: Cyclopentenone-fused derivatives.
Figure 27: Spiro-fused derivatives and a related ring-opened derivative.
Figure 28: Lactones-fused and lactone-substituted derivatives.
Scheme 2: Biosynthesis of alternariol [324].
Scheme 3: Biosynthesis of alternariol and its immediate successors with the genes involved in the respective ...
Scheme 4: Presumed formation of altenuene and its diastereomers and of botrallin.
Scheme 5: Presumed formation of altenuic acids and related compounds.
Scheme 6: A selection of plausible biosynthetic paths to cyclopenta-fused metabolites. (No stereochemistry is...
Scheme 7: Biomimetic synthesis of alternariol (1) by Harris and Hay [66].
Scheme 8: Total synthesis of alternariol (1) by Subba Rao et al. using a Diels–Alder approach [34].
Scheme 9: Total synthesis of alternariol (1) using a Suzuki strategy by Koch and Podlech [62], improved by Kim et...
Scheme 10: Total synthesis of alternariol (1) using an intramolecular biaryl coupling by Abe et al. [63].
Scheme 11: Total synthesis of altenuene (54) and isoaltenuene (55) by Podlech et al. [249].
Scheme 12: Total synthesis of neoaltenuene (69) by Podlech et al. [35].
Scheme 13: Total synthesis of TMC-264 (79) by Tatsuta et al. [185].
Scheme 14: Total synthesis of cephalosol (99) by Koert et al. [304].
Beilstein J. Org. Chem. 2024, 20, 1746–1757, doi:10.3762/bjoc.20.153
Graphical Abstract
Scheme 1: Formation of phenoxonium cation in the anodic oxidation of phenol performed under neutral or weakly...
Scheme 2: Anodic oxidation reported by Swenton et al. [37].
Figure 1: Cyclic voltammograms of PAPs first scan at 0.1 V/s in 0.1 M [NBu4] [PF6] in MeCN and UV–vis spectra...
Scheme 3: Proposed mechanism for the formation of p-dimethoxy acetals in the anodic oxidation of 1b and 3b.
Figure 2: Resonance structures of the phenoxonium cation formed from 2-chrysenol (3a).
Beilstein J. Org. Chem. 2019, 15, 1722–1757, doi:10.3762/bjoc.15.168
Graphical Abstract
Figure 1: Examples of three-carbon chirons.
Figure 2: Structures of derivatives of N-(1-phenylethyl)aziridine-2-carboxylic acid 5–8.
Figure 3: Synthetic equivalency of aziridine aldehydes 6.
Scheme 1: Synthesis of N-(1-phenylethyl)aziridine-2-carboxylates 5. Reagents and conditions: a) TEA, toluene,...
Scheme 2: Absolute configuration at C2 in (2S,1'S)-5a. Reagents and conditions: a) 20% HClO4, 80 °C, 30 h the...
Scheme 3: Major synthetic strategies for a 2-ketoaziridine scaffold [R* = (R)- or (S)-1-phenylethyl; R′ = Alk...
Scheme 4: Synthesis of cyanide (2S,1'S)-13. Reagents and conditions: a) NH3, EtOH/H2O, rt, 72 h; b) Ph3P, CCl4...
Scheme 5: Synthesis of key intermediates (R)-16 and (R)-17 for (R,R)-formoterol (14) and (R)-tamsulosin (15)....
Scheme 6: Synthesis of mitotic kinesin inhibitors (2R/S,1'R)-23. Reagents and conditions: a) H2, Pd(OH)2, EtO...
Scheme 7: Synthesis of (R)-mexiletine ((R)-24). Reagents and conditions: a) TsCl, TEA, DMAP, CH2Cl2, rt, 1 h;...
Scheme 8: Synthesis of (−)-cathinone ((S)-27). Reagents and conditions: a) PhMgBr, ether, 0 °C; b) H2, 10% Pd...
Scheme 9: Synthesis of N-Boc-norpseudoephedrine ((1S,2S)-(+)-29) and N-Boc-norephedrine ((1R,2S)-29). Reagent...
Scheme 10: Synthesis of (−)-ephedrine ((1R,2S)-31). Reagents and conditions: a) TfOMe, MeCN then NaBH3CN, rt; ...
Scheme 11: Synthesis of xestoaminol C ((2S,3R)-35), 3-epi-xestoaminol C ((2S,3S)-35) and N-Boc-spisulosine ((2S...
Scheme 12: Synthesis of ʟ-tryptophanol ((S)-41). Reagents and conditions: a) CDI, MeCN, rt, 1 h then TMSI, MeC...
Scheme 13: Synthesis of ʟ-homophenylalaninol ((S)-42). Reagents and conditions: a) NaH, THF, 0 °C to −78 °C, 1...
Scheme 14: Synthesis of ᴅ-homo(4-octylphenyl)alaninol ((R)-47) and a sphingolipid analogue (R)-48. Reagents an...
Scheme 15: Synthesis of florfenicol ((1R,2S)-49). Reagents and conditions: a) (S)-1-phenylethylamine, TEA, MeO...
Scheme 16: Synthesis of natural tyroscherin ((2S,3R,6E,8R,10R)-55). Reagents and conditions: a) I(CH2)3OTIPS, t...
Scheme 17: Syntheses of (−)-hygrine (S)-61, (−)-hygroline (2S,2'S)-62 and (−)-pseudohygroline (2S,2'R)-62. Rea...
Scheme 18: Synthesis of pyrrolidine (3S,3'R)-68, a fragment of the fluoroquinolone antibiotic PF-00951966. Rea...
Scheme 19: Synthesis of sphingolipid analogues (R)-76. Reagents and conditions: a) BnBr, Mg, THF, reflux, 6 h;...
Scheme 20: Synthesis of ᴅ-threo-PDMP (1R,2R)-81. Reagents and conditions: a) TMSCl, NaI, MeCN, rt, 1 h 50 min,...
Scheme 21: Synthesis of the sphingolipid analogue SG-14 (2S,3S)-84. Reagents and conditions: a) LiAlH4, THF, 0...
Scheme 22: Synthesis of the sphingolipid analogue SG-12 (2S,3R)-88. Reagents and conditions: a) 1-(bromomethyl...
Scheme 23: Synthesis of sphingosine-1-phosphate analogues DS-SG-44 and DS-SG-45 (2S,3R)-89a and (2S,3R)-89a. R...
Scheme 24: Synthesis of N-Boc-safingol ((2S,3S)-95) and N-Boc-ᴅ-erythro-sphinganine ((2S,3R)-95). Reagents and...
Scheme 25: Synthesis of ceramide analogues (2S,3R)-96. Reagents and conditions: a) NaBH4, ZnCl2, MeOH, −78 °C,...
Scheme 26: Synthesis of orthogonally protected serinols, (S)-101 and (R)-102. Reagents and conditions: a) BnBr...
Scheme 27: Synthesis of N-acetyl-3-phenylserinol ((1R,2R)-105). Reagents and conditions: a) AcOH, CH2Cl2, refl...
Scheme 28: Synthesis of (S)-linezolid (S)-107. Reagents and conditions: a) LiAlH4, THF, 0 °C to reflux; b) Boc2...
Scheme 29: Synthesis of (2S,3S,4R)-2-aminooctadecane-1,3,4-triol (ᴅ-ribo-phytosphingosine) (2S,3S,4R)-110. Rea...
Scheme 30: Syntheses of ᴅ-phenylalanine (R)-116. Reagents and conditions: a) AcOH, CH2Cl2, reflux, 4 h; b) MsC...
Scheme 31: Synthesis of N-Boc-ᴅ-3,3-diphenylalanine ((R)-122). Reagents and conditions: a) PhMgBr, THF, −78 °C...
Scheme 32: Synthesis of ethyl N,N’-di-Boc-ʟ-2,3-diaminopropanoate ((S)-125). Reagents and conditions: a) NaN3,...
Scheme 33: Synthesis of the bicyclic amino acid (S)-(+)-127. Reagents and conditions: a) BF3·OEt2, THF, 60 °C,...
Scheme 34: Synthesis of lacosamide, (R)-2-acetamido-N-benzyl-3-methoxypropanamide (R)-130. Reagents and condit...
Scheme 35: Synthesis of N-Boc-norfuranomycin ((2S,2'R)-133). Reagents and conditions: a) H2C=CHCH2I, NaH, THF,...
Scheme 36: Synthesis of MeBmt (2S,3R,4R,6E)-139. Reagents and conditions: a) diisopropyl (S,S)-tartrate (E)-cr...
Scheme 37: Synthesis of (+)-polyoxamic acid (2S,3S,4S)-144. Reagents and conditions: a) AD-mix-α, MeSO2NH2, t-...
Scheme 38: Synthesis of the protected 3-hydroxy-ʟ-glutamic acid (2S,3R)-148. Reagents and conditions: a) LiHMD...
Scheme 39: Synthesis of (+)-isoserine (R)-152. Reagents and conditions: a) AcCl, MeCN, rt, 0.5 h then Na2CO3, ...
Scheme 40: Synthesis of (3R,4S)-N3-Boc-3,4-diaminopentanoic acid (3R,4S)-155. Reagents and conditions: a) Ph3P...
Scheme 41: Synthesis of methyl (2S,3S,4S)-4-(dimethylamino)-2,3-dihydroxy-5-methoxypentanoate (2S,3S,4S)-159. ...
Scheme 42: Syntheses of methyl (3S,4S) 4,5-di-N-Boc-amino-3-hydroxypentanoate ((3S,4S)-164), methyl (3S,4S)-4-N...
Scheme 43: Syntheses of (3R,5S)-5-(aminomethyl)-3-(4-methoxyphenyl)dihydrofuran-2(3H)-one ((3R,5S)-168). Reage...
Scheme 44: Syntheses of a series of imidazolin-2-one dipeptides 175–177 (for R' and R'' see text). Reagents an...
Scheme 45: Syntheses of (2S,3S)-N-Boc-3-hydroxy-2-hydroxymethylpyrrolidine ((2S,3S)-179). Reagents and conditi...
Scheme 46: Syntheses of enantiomers of 1,4-dideoxy-1,4-imino-ʟ- and -ᴅ-lyxitols (2S,3R,4S)-182 and (2R,3S,4R)-...
Scheme 47: Synthesis of 1,4-dideoxy-1,4-imino-ʟ-ribitol (2S,3S,4R)-182. Reagents and conditions: a) AcOH, CH2Cl...
Scheme 48: Syntheses of 1,4-dideoxy-1,4-imino-ᴅ-arabinitol (2R,3R,4R)-182 and 1,4-dideoxy-1,4-imino-ᴅ-xylitol ...
Scheme 49: Syntheses of natural 2,5-imino-2,5,6-trideoxy-ʟ-gulo-heptitol ((2S,3R,4R,5R)-184) and its C4 epimer...
Scheme 50: Syntheses of (−)-dihydropinidine ((2S,6R)-187a) (R = C3H7) and (2S,6R)-isosolenopsins (2S,6R)-187b ...
Scheme 51: Syntheses of (+)-deoxocassine ((2S,3S,6R)-190a, R = C12H25) and (+)-spectaline ((2S,3S,6R)-190b, R ...
Scheme 52: Synthesis of (−)-microgrewiapine A ((2S,3R,6S)-194a) and (+)-microcosamine A ((2S,3R,6S)-194b). Rea...
Scheme 53: Syntheses of ʟ-1-deoxynojirimycin ((2S,3S,4S,5R)-200), ʟ-1-deoxymannojirimycin ((2S,3S,4S,5S)-200) ...
Scheme 54: Syntheses of 1-deoxy-ᴅ-galacto-homonojirimycin (2R,3S,4R,5S)-211. Reagents and conditions: a) MeONH...
Scheme 55: Syntheses of 7a-epi-hyacinthacine A1 (1S,2R,3R,7aS)-220. Reagents and conditions: a) TfOTBDMS, 2,6-...
Scheme 56: Syntheses of 8-deoxyhyacinthacine A1 ((1S,2R,3R,7aR)-221). Reagents and conditions: a) H2, Pd/C, PT...
Scheme 57: Syntheses of (+)-lentiginosine ((1S,2S,8aS)-227). Reagents and conditions: a) (EtO)2P(O)CH2COOEt, L...
Scheme 58: Syntheses of 8-epi-swainsonine (1S,2R,8S,8aR)-231. Reagents and conditions: a) Ph3P=CHCOOMe, MeOH, ...
Scheme 59: Synthesis of a protected vinylpiperidine (2S,3R)-237, a key intermediate in the synthesis of (−)-sw...
Scheme 60: Synthesis of a modified carbapenem 245. Reagents and conditions: a) AcOEt, LiHMDS, THF, −78 °C, 1.5...
Beilstein J. Org. Chem. 2018, 14, 470–483, doi:10.3762/bjoc.14.33
Graphical Abstract
Figure 1: Chemical structure of UDCA.
Figure 2: Chemical structures of bile acids and salts.
Figure 3: Comparison between Wolff–Kishner and Mozingo reduction. Notably the overall chemical reaction is th...
Figure 4: Reaction catalysed by the 12α-HSDH; the 12-OH group of CA or UCA is oxidized yielding 12-oxo-CDCA o...
Figure 5: Epimerization reaction catalysed by the 7α-HSDH and 7β-HSDH; the 7α-OH group of CA (R = OH) or CDCA...
Figure 6: Overview of the chemoenzymatic process for the production of UDCA from CA: The oxidation, reduction...
Figure 7: Schematic representation of the flow reactor for the continuous conversion of CDCA to UDCA [93].
Figure 8: Chemoenzymatic pathways for the formation of UDCA from CA that profit by the C7 hydroxylation activ...
Beilstein J. Org. Chem. 2017, 13, 106–110, doi:10.3762/bjoc.13.13
Graphical Abstract
Scheme 1: Automated synthesis of 4a.
Figure 1: Full picture of ChemKonzert, showing two reaction vessels (RF1 and RF2), a centrifugal separator (S...
Beilstein J. Org. Chem. 2016, 12, 1512–1550, doi:10.3762/bjoc.12.148
Graphical Abstract
Scheme 1: Schematic description of the cyclisation reaction catalysed by TE domains. In most cases, the nucle...
Scheme 2: Mechanisms for the formation of oxygen heterocycles. The degree of substitution can differ from tha...
Scheme 3: Pyran-ring formation in pederin (24) biosynthesis. Incubation of recombinant PedPS7 with substrate ...
Scheme 4: The domain AmbDH3 from ambruticin biosynthesis catalyses the dehydration of 25 and subsequent cycli...
Scheme 5: SalBIII catalyses dehydration of 29 and subsequent cyclisation to tetrahydropyran 30 [18].
Figure 1: All pyranonaphtoquinones contain either the naphtha[2,3-c]pyran-5,10-dione (32) or the regioisomeri...
Scheme 6: Pyran-ring formation in actinorhodin (34) biosynthesis. DNPA: 4-dihydro-9-hydroxy-1-methyl-10-oxo-3H...
Scheme 7: Pyran formation in granaticin (36) biosynthesis. DNPA: 4-dihydro-9-hydroxy-1-methyl-10-oxo-3H-napht...
Scheme 8: Pyran formation in alnumycin (37) biosynthesis. Adapted from [21].
Scheme 9: Biosynthesis of pseudomonic acid A (61). The pyran ring is initially formed in 57 after dehydrogena...
Scheme 10: Epoxidation–cyclisation leads to the formation of the tetrahydropyran ring in the western part of t...
Scheme 11: a) Nonactin (70) is formed from heterodimers of (−)(+)-dimeric nonactic acid and (+)(−)-dimeric non...
Figure 2: Pamamycins (73) are macrodiolide antibiotics containing three tetrahydrofuran moieties, which are a...
Scheme 12: A PS domain homolog in oocydin A (76) biosynthesis is proposed to catalyse furan formation via an o...
Scheme 13: Mechanism of oxidation–furan cyclisation by AurH, which converts (+)-deoxyaureothin (77) into (+)-a...
Scheme 14: Leupyrrin A2 (80) and the proposed biosynthesis of its furylidene moiety [69,70].
Scheme 15: Asperfuranone (93) biosynthesis, adapted from [75].
Figure 3: The four major aflatoxins produced by Aspergilli are the types B1, B2, G1 and G2 (94–97). In the di...
Scheme 16: Overview on aflatoxin B1 (94) biosynthesis. HOMST = 11-hydroxy-O-methylsterigmatocystin [78,79,82-106].
Scheme 17: A zipper mechanism leads to the formation of oxygen heterocycles in monensin biosynthesis [109-111].
Scheme 18: Formation of the 2,6-dioxabicyclo[3.2.1]octane (DBO) ring system in aurovertin B (118) biosynthesis ...
Figure 4: Structures of the epoxide-containing polyketides epothilone A (119) and oleandomycin (120) [123-125].
Scheme 19: Structures of phoslactomycin B (121) (a) and jerangolid A (122) (b). The heterocycle-forming steps ...
Scheme 20: a) Structures of rhizoxin (130) and cycloheximide (131). Model for the formation of δ-lactones (b) ...
Scheme 21: EncM catalyses a dual oxidation sequence and following processing of the highly reactive intermedia...
Figure 5: Mesomeric structures of tetronates [138,139].
Figure 6: Structures of tetronates for which gene clusters have been sequenced. The tetronate moiety is shown...
Scheme 22: Conserved steps for formation and processing in several 3-acyl-tetronate biosynthetic pathways were...
Scheme 23: In versipelostatin A (153) biosynthesis, VstJ is a candidate enzyme for catalysing the [4 + 2] cycl...
Scheme 24: a) Structures of some thiotetronate antibiotics. b) Biosynthesis of thiolactomycin (165) as propose...
Scheme 25: Aureusidine synthase (AS) catalyses phenolic oxidation and conjugate addition of chalcones leading ...
Scheme 26: a) Oxidative cyclisation is a key step in the biosynthesis of spirobenzofuranes 189, 192 and 193. b...
Scheme 27: A bicyclisation mechanism forms a β-lactone and a pyrrolidinone and removes the precursor from the ...
Scheme 28: Spontaneous cyclisation leads to off-loading of ebelactone A (201) from the PKS machinery [163].
Scheme 29: Mechanisms for the formation of nitrogen heterocycles.
Scheme 30: Biosynthesis of highly substituted α-pyridinones. a) Feeding experiments confirmed the polyketide o...
Scheme 31: Acridone synthase (ACS) catalyses the formation of 1,3-dihydroxy-N-methylacridone (224) by condensa...
Scheme 32: A Dieckmann condensation leads to the formation of a 3-acyl-4-hydroxypyridin-2-one 227 and removes ...
Scheme 33: a) Biosynthesis of the pyridinone tenellin (234). b) A radical mechanism was proposed for the ring-...
Scheme 34: a) Oxazole-containing PKS–NRPS-derived natural products oxazolomycin (244) and conglobatin (245). b...
Scheme 35: Structure of tetramic acids 251 (a) and major tautomers of 3-acyltetramic acids 252a–d (b). Adapted...
Scheme 36: Equisetin biosynthesis. R*: terminal reductive domain. Adapted from [202].
Scheme 37: a) Polyketides for which a similar biosynthetic logic was suggested. b) Pseurotin A (256) biosynthe...
Figure 7: Representative examples of PTMs with varying ring sizes and oxidation patterns [205,206].
Scheme 38: Ikarugamycin biosynthesis. Adapted from [209-211].
Scheme 39: Tetramate formation in pyrroindomycin aglycone (279) biosynthesis [213-215].
Scheme 40: Dieckmann cyclases catalyse tetramate or 2-pyridone formation in the biosynthesis of, for example, ...
Beilstein J. Org. Chem. 2015, 11, 155–161, doi:10.3762/bjoc.11.15
Graphical Abstract
Scheme 1: Reagents and conditions: (A) p-thiocresol, BF3∙Et2O, CH2Cl2, 24 h, rt, 81%; (B) i) NaOMe, MeOH, 12 ...
Figure 1: Degradation of 4’F-TF antigen derivative 12 and its natural (synthetic) congener 13 by β-galactosid...
Scheme 2: Reagents and conditions: (A) aq Na2CO3, pH 8.0, EtOH/H2O (1:1); (B) aq Na2HPO4, pH 9.5, 5 d.
Figure 2: ELISA of the antiserum of mouse 2 induced by 4’F-TF-Thr6-MUC1(20)-TTox vaccine 18b; coat: 5 µg/mL 4...
Figure 3: Determination of the isotypes of the antibodies induced by 4’F-TF-Thr6-MUC1(20)-TTox vaccine 18b (a...
Figure 4: FACS analysis of the binding of MCF-7 tumor cells by the antiserum of mouse 2 induced by vaccinatio...
Beilstein J. Org. Chem. 2014, 10, 1749–1758, doi:10.3762/bjoc.10.182
Graphical Abstract
Scheme 1: Approach to divalent carbohydrate mimetics 1 with rigid spacer and monovalent analogues 2.
Scheme 2: Synthesis of (Z)-nitrone 6. Conditions: a) LiAlH4, THF, 1 h, rt; b) 1. NaIO4, CH3CN/H2O, 1 h, rt; 2...
Scheme 3: [3 + 3]-Cyclization of (Z)-nitrone 6 with lithiated allene 9. Conditions: a) n-BuLi, THF, 15 min, −...
Scheme 4: Synthesis of 1,2-oxazine 4 by acetal formation from 10. Conditions: a) 1-bromo-4-(dimethoxymethyl)b...
Scheme 5: Synthesis of bicyclic ketone 11 by Lewis acid-induced rearrangement and reduction to alcohols 12a a...
Scheme 6: Synthesis of bicyclic diols 15 and of trityl-protected bicyclic 1,2-oxazine 16. Conditions: a) SnCl4...
Scheme 7: Hydrogenolyses of bicyclic 1,2-oxazine derivatives 15a and 15b. Conditions: a) H2, Pd/C, MeOH, EtOA...
Scheme 8: Suzuki cross-coupling of 15a leading to biphenyl derivative 18 and hydrogenolysis to 19. Conditions...
Scheme 9: Synthesis of N-benzylated p-terphenyl derivative 21 by Suzuki cross-coupling of 12a with 20 and sub...
Scheme 10: Attempted reductive cleavage of the N–O bond of compound 21 by samarium diiodide and reaction of 12a...
Scheme 11: Deprotection of compound 21 and samarium diiodide-mediated reaction of 26. Conditions: a) TBAF, THF...
Scheme 12: Suzuki cross-coupling of compound 16. Conditions: Pd(PPh3)2Cl2, 2 M Na2CO3, DMF, 80 °C, 3 d.
Scheme 13: Hydrogenolysis of compound 27 and samarium diiodide-mediated reaction leading to compounds 30 and 31...
Beilstein J. Org. Chem. 2013, 9, 1526–1532, doi:10.3762/bjoc.9.174
Graphical Abstract
Scheme 1: Transacetalization of acetal 7.
Scheme 2: Thioacetalization of hexanal with Re2O7.
Scheme 3: Proposed mechanistic pathway.
Beilstein J. Org. Chem. 2013, 9, 705–709, doi:10.3762/bjoc.9.80
Graphical Abstract
Figure 1: Structure of the synthesized trisaccharide core found in kankanose, kankanoside F, H1, H2 and I iso...
Scheme 1: Reagents: (a) 0.1 M CH3ONa, CH3OH, room temperature, 3 h, 98% for compound 5, 94% for compound 1; (...
Beilstein J. Org. Chem. 2012, 8, 522–527, doi:10.3762/bjoc.8.59
Graphical Abstract
Figure 1: Synthetic route to transform oxyglycal I to a septanoside V.
Scheme 1: Reaction conditions: (i) NaOMe, PhMe, reflux, 8 h; (ii) methyl acrylate (for 3); tert-butyl acrylat...
Scheme 2: Reaction conditions: (i) phenylboronic acid (for 8); 4-methoxyphenylboronic acid (for 9); 3-methylp...
Scheme 3: Reaction conditions: (i) phenylacetylene (for 11); oct-1-yne (for 12); Pd(PPh3)2Cl2 (20 mol %), CuI...
Scheme 4: Reaction conditions: (i) Pd/C (10 %), H2, MeOH, rt, 24 h; (ii) NaBH4, MeOH, 0 °C to rt, 3 h.
Beilstein J. Org. Chem. 2012, 8, 413–420, doi:10.3762/bjoc.8.46
Graphical Abstract
Figure 1: Monobenzylated methyl α- and β-D-gluco- and galactopyranoside acceptors 1–6.
Figure 2: Benzylated glycopyranosyl halide donors 7–9.
Scheme 1: Synthesis of monobenzylated glucopyranosyl acceptors 1–4. Reagents and conditions: (a) Benzaldehyde...
Scheme 2: Synthesis of 3-O-monobenzylated gluco- und galactopyranosyl acceptors 5 and 6. Reagents and conditi...
Scheme 3: Synthesis of 2,3,4,6-tetra-O-benzyl-α-D-galactopyranosyl chloride (8) and 2,3,4,6-tetra-O-benzyl-α-...
Beilstein J. Org. Chem. 2007, 3, No. 21, doi:10.1186/1860-5397-3-21
Graphical Abstract
Scheme 1: Saigo's cycloisomerisation reaction under Pauson-Khand conditions.
Scheme 2: Pauson-Khand reaction and tether-cleavage in wet acetonitrile.
Scheme 3: Silyl-tethered allenic Pauson-Khand reaction reported by Brummond.
Scheme 4: Intramolecular Pauson-Khand reaction of allyldimethyl- and allyldiphenylsilyl propargyl ethers repo...
Scheme 5: Synthesis and attempted Pauson-Khand reactions of vinyldimethylsilyl- and vinyldiphenylsilyl ethers....
Figure 1: Functionalised acetylenes prepared and used in silyl ether-tethered Pauson-Khand reactions. Yields ...
Figure 2: Chain-functionalised acetylenes prepared and used in silyl ether-tethered Pauson-Khand reactions. Y...
Figure 3: Possible structure of THF-oxidation/insertion product.
Scheme 6: Model Pauson-Khand reaction of allyltrimethylsilane.
Scheme 7: Preparation of allyldiisopropylsilyl ethers.
Scheme 8: Pauson-Khand reaction of allyldiisopropylsilyl ethers.
Scheme 9: Preparation of allyldiisopropylsilanes.
Scheme 10: Attempted Mitsunobu reactions of diisopropylsilanols.
Scheme 11: Preparation of alkynic diisopropylsilanes.
Scheme 12: Preparation of allyldiisopropylsilyl ethers.
Scheme 13: Preparation of acetals from dichlorodiphenylsilane.
Scheme 14: Attempted Pauson-Khand reaction of allylpropargyldiphenylsilyl acetal.
Scheme 15: Proposed diisopropylsilyl acetal formation.
Scheme 16: Attempted allylpropargyldiisopropylsilyl acetal formation.
Scheme 17: Attempted allylpropargyldiisopropylsilyl acetal formation.
Scheme 18: Preparation of silicon-tethered Pauson-Khand precursors.
Scheme 19: Failed Pauson-Khand reaction of a silicon-tethered substrate.